Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Decibel Therapeutics (Nasdaq: DBTX) announced the European Medicines Agency's (EMA) positive opinion on orphan drug designation for DB-OTO, its gene therapy for congenital hearing loss due to otoferlin gene mutations. This designation supports Decibel's Phase 1/2 trial initiation planned for the first half of 2023. The orphan drug status enables access to various regulatory incentives, including potential market exclusivity for ten years in the EU. Currently, no approved treatments exist for this condition, highlighting the urgent need for innovative solutions in this area.
BOSTON, March 28, 2023 – Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company, announced that CEO Laurence Reid, Ph.D., will participate in a fireside chat at the Guggenheim Healthcare Talks on April 3, 2023, at 9:00 a.m. E.T. in New York, NY. The event will focus on genomic medicines and rare diseases. Investors can access a live webcast from Decibel's website, with a replay available for 90 days after the event. Decibel Therapeutics aims to develop treatments for hearing and balance disorders, leveraging a proprietary platform that includes gene therapy technologies and expertise in inner ear biology.
Decibel Therapeutics (Nasdaq: DBTX) has appointed Matthew Kapusta to its Board of Directors, signaling a strategic enhancement as the company advances its gene therapy initiatives targeting hearing and balance disorders. Kapusta, an accomplished life sciences executive with 25 years of experience, previously led uniQure in developing the first approved gene therapy for hemophilia B. His expertise is expected to bolster Decibel’s approach in bringing transformative treatments to patients. As the company prepares for the clinical evaluation of its first gene therapy product, this leadership change is positioned to strengthen Decibel’s capabilities in the burgeoning field of gene therapy.